Friday, March 5, 2021

Regulus Therapeutics Inc. [RGLS] fell -15.01% so far this year. What now?

Must read

Armstrong Flooring Inc (AFI) Hitting the mark

Armstrong Flooring Inc (AFI) ‎stock got some oxygen when the company publicly announced to sell its production facility and real state property of theSouth...

A look IntoAtomera Incorporated (ATOM)

Atomera Incorporated (NASDAQ: ATOM) has announced the successful sale of one of its development projects.  ATOM stock was last closed at $25.27. Based on...

Regulus Therapeutics Inc. [NASDAQ: RGLS] surged by $0.05 during the normal trading session on Friday and reaching a high of $0.79 during the day while it closed the day at $0.76. The company report on December 2, 2020 that Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing. RGLS4326 is a first in class anti-miR-17 therapy currently in Phase 1b clinical development in ADPKD patients. The Phase 1b trial is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD. This study will evaluate RGLS4326 for safety, pharmacokinetics, and pharmacodynamic effects on the levels of polycystin 1 (PC1) and polycystin 2 (PC2). Due to a mutation in the PKD genes, patients with ADPKD have been reported to have low levels of PC1 and PC2, the proteins encoded by the PKD1 and PKD2 genes, respectively. This study is designed to assess whether different dose levels of RGLS4326 can increase levels of PC1 and PC2 in ADPKD patients. Regulus has elected to collaborate with Bio-Techne for the development of high-performance biomarker assays to support the assessment of PC1 and PC2 levels using the fully automated Simple Western instrument as a read-out. The first cohort is expected to enroll up to nine patients who will receive RGLS4326 every two weeks over a six-week period. The Company anticipates availability of results from the first cohort by the end of Q1 2021.

Regulus Therapeutics Inc. stock has also gained 18.80% of its value over the past 7 days. However, RGLS stock has inclined by 64.47% in the 3 months of the year. Over the past six months meanwhile, it has lost -10.83% and lost -15.01% year-on date.

The market cap for RGLS stock reached $27.81 million, with 38.14 million shares outstanding and 37.44 million shares in the current float. Compared to the average trading volume of 455.90K shares, RGLS reached a trading volume of 1180433 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Regulus Therapeutics Inc. [RGLS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RGLS shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RGLS stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

B. Riley FBR Inc. have made an estimate for Regulus Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2018. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on January 05, 2018, representing the official price target for Regulus Therapeutics Inc. stock. Previously, the target price had yet another drop from $5 to $2.50, while Chardan Capital Markets kept a Buy rating on RGLS stock. On March 06, 2017, analysts decreased their price target for RGLS shares from 8 to 6.

The Average True Range (ATR) for Regulus Therapeutics Inc. is set at 0.06, with the Price to Sales ratio for RGLS stock in the period of the last 12 months amounting to 5.56. The Price to Book ratio for the last quarter was 3.78, with the Price to Cash per share for the same quarter was set at 0.48.

RGLS stock trade performance evaluation

Regulus Therapeutics Inc. [RGLS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.80. With this latest performance, RGLS shares gained by 56.67% in over the last four-week period, additionally sinking by -10.83% over the last 6 months – not to mention a drop of 0.00% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RGLS stock in for the last two-week period is set at 74.04, with the RSI for the last a single of trading hit 78.93, and the three-weeks RSI is set at 68.93 for Regulus Therapeutics Inc. [RGLS]. The present Moving Average for the last 50 days of trading for this stock 0.5537, while it was recorded at 0.6971 for the last single week of trading, and 0.6246 for the last 200 days.

Regulus Therapeutics Inc. [RGLS]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Regulus Therapeutics Inc. [RGLS] shares currently have an operating margin of -246.40. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13.

Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 76.57. Additionally, RGLS Total Debt to Total Capital is recorded at 43.36, with Total Debt to Total Assets ending up at 36.42. Long-Term Debt to Equity for the company is recorded at 0.28, with the Long-Term Debt to Total Capital now at 0.16.

Reflecting on the efficiency of the workforce at the company, Regulus Therapeutics Inc. [RGLS] managed to generate an average of -$885,333 per employee. Receivables Turnover for the company is 11.71 with a Total Asset Turnover recorded at a value of 0.20.Regulus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.

Earnings per share (EPS) analysis for Regulus Therapeutics Inc. [RGLS] stock

With the latest financial reports released by the company, Regulus Therapeutics Inc. posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RGLS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Regulus Therapeutics Inc. go to 39.60%.

Regulus Therapeutics Inc. [RGLS]: Insider Ownership positions

There are presently around $6 million, or 23.00% of RGLS stock, in the hands of institutional investors. The top three institutional holders of RGLS stocks are: BVF INC/IL with ownership of 3,217,480, which is approximately 121.895% of the company’s market cap and around 0.60% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 2,052,455 shares of the stock with an approximate value of $1.55 million in RGLS stocks shares; and SARISSA CAPITAL MANAGEMENT LP, currently with $1.4 million in RGLS stock with ownership of nearly 0% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Regulus Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 11 institutional holders increased their position in Regulus Therapeutics Inc. [NASDAQ:RGLS] by around 2,130,391 shares. Additionally, 12 investors decreased positions by around 484,616 shares, while 12 investors held positions by with 5,284,207 shares. The mentioned changes placed institutional holdings at 7,899,214 shares, according to the latest SEC report filing. RGLS stock had 3 new institutional investments in for a total of 194,348 shares, while 8 institutional investors sold positions of 462,204 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

A look IntoAtomera Incorporated (ATOM)

Atomera Incorporated (NASDAQ: ATOM) has announced the successful sale of one of its development projects.  ATOM stock was last closed at $25.27. Based on...

Armstrong Flooring Inc (AFI) Hitting the mark

Armstrong Flooring Inc (AFI) ‎stock got some oxygen when the company publicly announced to sell its production facility and real state property of theSouth...

The Goodyear Tire & Rubber Company (GT): Keeping an Eye On The Long Term

The Goodyear Tire & Rubber Company (NASDAQ: GT) has acquired rival Cooper Tire & Rubber Company (NYSE: CTB) for $2.8 billion. The takeover will...

OCUL stock: Ocular Therapeutix (OCUL) Is Better Than You Think

Ocular Therapeutix (OCUL) has performed well over the past year. OCUL has experienced a 248.76% gain in the last year, while its stock has...

Examining the Technicals of Levi Strauss & Co (NYSE: LEVI)

Levi Strauss & Co (NYSE: LEVI), one of the world's most famous denim brands, is recovering from the COVID-19 crisis. As a result of...

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.